{"id":774,"date":"2024-09-23T21:05:03","date_gmt":"2024-09-23T19:05:03","guid":{"rendered":"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/"},"modified":"2024-09-23T21:05:05","modified_gmt":"2024-09-23T19:05:05","slug":"une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente","status":"publish","type":"post","link":"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/","title":{"rendered":"Une incidence de r\u00e9ponse \u00e9lev\u00e9e a \u00e9t\u00e9 observ\u00e9e pour l’axatilimab dans le traitement de la maladie du greffon contre l’h\u00f4te r\u00e9fractaire et r\u00e9currente"},"content":{"rendered":"
\n
\n
\n
\n<\/figure><\/div>\n<\/div>\n

Chez les patients atteints d’une maladie du greffon contre l’h\u00f4te (GVHD) r\u00e9currente ou r\u00e9fractaire, l’anticorps bloquant le r\u00e9cepteur du facteur de stimulation des colonies 1 (CSF1R) axatilimab entra\u00eene une incidence \u00e9lev\u00e9e de r\u00e9ponse globale, selon une \u00e9tude publi\u00e9e dans la revue Journal de m\u00e9decine de la Nouvelle-Angleterre<\/i>.<\/p>\n

Le Dr Daniel Wolff, de l’h\u00f4pital universitaire de Ratisbonne en Allemagne, et ses coll\u00e8gues ont examin\u00e9 trois doses diff\u00e9rentes d’axatilimab dans une \u00e9tude de phase 2 portant sur des patients atteints de GVHD chronique r\u00e9currente ou r\u00e9fractaire.<\/p>\n

Les patients ont \u00e9t\u00e9 r\u00e9partis de mani\u00e8re al\u00e9atoire pour recevoir de l’axatilimab, administr\u00e9 par voie intraveineuse, \u00e0 une dose de 0,3 mg, 1 mg ou 3 mg par kilogramme de poids corporel toutes les deux semaines, toutes les deux semaines et toutes les quatre semaines, respectivement (80, 81 et 80 patients dans les groupes de doses de 0,3 mg, 1 mg et 3 mg, respectivement). Le crit\u00e8re d’\u00e9valuation principal \u00e9tait la r\u00e9ponse globale au cours des six premiers cycles (r\u00e9ponse compl\u00e8te ou partielle).<\/p>\n

Les chercheurs ont constat\u00e9 que le crit\u00e8re d’\u00e9valuation principal a \u00e9t\u00e9 atteint dans tous les groupes de dose ; une r\u00e9ponse globale a \u00e9t\u00e9 observ\u00e9e chez 74, 67 et 50 % des patients dans les groupes de dose de 0,3 mg, 1 mg et 3 mg, respectivement. Dans les trois groupes de dose, il y a eu une r\u00e9duction de plus de 5 points sur l’\u00e9chelle de sympt\u00f4mes de Lee modifi\u00e9e chez 60, 69 et 41 % des patients, respectivement. Les anomalies transitoires de laboratoire dose-d\u00e9pendantes li\u00e9es au blocage du CSF1R \u00e9taient les \u00e9v\u00e9nements ind\u00e9sirables les plus fr\u00e9quents.<\/p>\n

\u00ab L’\u00e9tude a atteint son crit\u00e8re d’\u00e9valuation principal et a montr\u00e9 l’efficacit\u00e9 de l’axatilimab chez les patients des trois groupes de doses, avec une r\u00e9ponse globale survenant chez 50 \u00e0 74 % des patients \u00bb, \u00e9crivent les auteurs.<\/p>\n

L\u2019\u00e9tude a \u00e9t\u00e9 financ\u00e9e par Incyte et Syndax Pharmaceuticals, qui fabriquent et d\u00e9livrent les licences d\u2019axatilimab.<\/p>\n

<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

Chez les patients atteints d’une maladie du greffon contre l’h\u00f4te (GVHD) r\u00e9currente ou r\u00e9fractaire, l’anticorps<\/p>\n","protected":false},"author":1,"featured_media":775,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[90,44,963,964,967,962,966,968,248,965,8,970,969,326,261,47],"class_list":["post-774","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-maladies","tag-contre","tag-dans","tag-elevee","tag-ete","tag-greffon","tag-incidence","tag-laxatilimab","tag-lhote","tag-maladie","tag-observee","tag-pour","tag-recurrente","tag-refractaire","tag-reponse","tag-traitement","tag-une","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"yoast_head":"\nUne incidence de r\u00e9ponse \u00e9lev\u00e9e a \u00e9t\u00e9 observ\u00e9e pour l'axatilimab dans le traitement de la maladie du greffon contre l'h\u00f4te r\u00e9fractaire et r\u00e9currente - RVH-Synergie.org<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Une incidence de r\u00e9ponse \u00e9lev\u00e9e a \u00e9t\u00e9 observ\u00e9e pour l'axatilimab dans le traitement de la maladie du greffon contre l'h\u00f4te r\u00e9fractaire et r\u00e9currente - RVH-Synergie.org\" \/>\n<meta property=\"og:description\" content=\"Chez les patients atteints d’une maladie du greffon contre l’h\u00f4te (GVHD) r\u00e9currente ou r\u00e9fractaire, l’anticorps\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/\" \/>\n<meta property=\"og:site_name\" content=\"RVH-Synergie\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-23T19:05:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T19:05:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1727118304_Une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"851\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Charles Martinez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Martinez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/\"},\"author\":{\"name\":\"Charles Martinez\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\"},\"headline\":\"Une incidence de r\u00e9ponse \u00e9lev\u00e9e a \u00e9t\u00e9 observ\u00e9e pour l’axatilimab dans le traitement de la maladie du greffon contre l’h\u00f4te r\u00e9fractaire et r\u00e9currente\",\"datePublished\":\"2024-09-23T19:05:03+00:00\",\"dateModified\":\"2024-09-23T19:05:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/\"},\"wordCount\":372,\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1727118304_Une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab.jpg\",\"keywords\":[\"contre\",\"dans\",\"\u00e9lev\u00e9e\",\"\u00e9t\u00e9\",\"greffon\",\"incidence\",\"laxatilimab\",\"lh\u00f4te\",\"maladie\",\"observ\u00e9e\",\"pour\",\"r\u00e9currente\",\"r\u00e9fractaire\",\"r\u00e9ponse\",\"traitement\",\"une\"],\"articleSection\":[\"Les maladies\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/\",\"name\":\"Une incidence de r\u00e9ponse \u00e9lev\u00e9e a \u00e9t\u00e9 observ\u00e9e pour l'axatilimab dans le traitement de la maladie du greffon contre l'h\u00f4te r\u00e9fractaire et r\u00e9currente - RVH-Synergie.org\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1727118304_Une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab.jpg\",\"datePublished\":\"2024-09-23T19:05:03+00:00\",\"dateModified\":\"2024-09-23T19:05:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/#primaryimage\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1727118304_Une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1727118304_Une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab.jpg\",\"width\":1280,\"height\":851,\"caption\":\"Une incidence de r\u00e9ponse \u00e9lev\u00e9e a \u00e9t\u00e9 observ\u00e9e pour l'axatilimab dans le traitement de la maladie du greffon contre l'h\u00f4te r\u00e9fractaire et r\u00e9currente\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/rvh-synergie.org\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Une incidence de r\u00e9ponse \u00e9lev\u00e9e a \u00e9t\u00e9 observ\u00e9e pour l’axatilimab dans le traitement de la maladie du greffon contre l’h\u00f4te r\u00e9fractaire et r\u00e9currente\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"name\":\"RVH-Synergie.org\",\"description\":\"RVH-Synergie, site ind\u00e9pendant d'informations sur la prise en charge des addictions.\",\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\",\"name\":\"RVH-Synergie.org\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"width\":512,\"height\":512,\"caption\":\"RVH-Synergie.org\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\",\"name\":\"Charles Martinez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"caption\":\"Charles Martinez\"},\"description\":\"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.\",\"sameAs\":[\"https:\/\/rvh-synergie.org\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Une incidence de r\u00e9ponse \u00e9lev\u00e9e a \u00e9t\u00e9 observ\u00e9e pour l'axatilimab dans le traitement de la maladie du greffon contre l'h\u00f4te r\u00e9fractaire et r\u00e9currente - RVH-Synergie.org","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/","og_locale":"fr_FR","og_type":"article","og_title":"Une incidence de r\u00e9ponse \u00e9lev\u00e9e a \u00e9t\u00e9 observ\u00e9e pour l'axatilimab dans le traitement de la maladie du greffon contre l'h\u00f4te r\u00e9fractaire et r\u00e9currente - RVH-Synergie.org","og_description":"Chez les patients atteints d’une maladie du greffon contre l’h\u00f4te (GVHD) r\u00e9currente ou r\u00e9fractaire, l’anticorps","og_url":"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/","og_site_name":"RVH-Synergie","article_published_time":"2024-09-23T19:05:03+00:00","article_modified_time":"2024-09-23T19:05:05+00:00","og_image":[{"width":1280,"height":851,"url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1727118304_Une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab.jpg","type":"image\/jpeg"}],"author":"Charles Martinez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Charles Martinez","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/#article","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/"},"author":{"name":"Charles Martinez","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560"},"headline":"Une incidence de r\u00e9ponse \u00e9lev\u00e9e a \u00e9t\u00e9 observ\u00e9e pour l’axatilimab dans le traitement de la maladie du greffon contre l’h\u00f4te r\u00e9fractaire et r\u00e9currente","datePublished":"2024-09-23T19:05:03+00:00","dateModified":"2024-09-23T19:05:05+00:00","mainEntityOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/"},"wordCount":372,"publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1727118304_Une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab.jpg","keywords":["contre","dans","\u00e9lev\u00e9e","\u00e9t\u00e9","greffon","incidence","laxatilimab","lh\u00f4te","maladie","observ\u00e9e","pour","r\u00e9currente","r\u00e9fractaire","r\u00e9ponse","traitement","une"],"articleSection":["Les maladies"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/","url":"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/","name":"Une incidence de r\u00e9ponse \u00e9lev\u00e9e a \u00e9t\u00e9 observ\u00e9e pour l'axatilimab dans le traitement de la maladie du greffon contre l'h\u00f4te r\u00e9fractaire et r\u00e9currente - RVH-Synergie.org","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/#primaryimage"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1727118304_Une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab.jpg","datePublished":"2024-09-23T19:05:03+00:00","dateModified":"2024-09-23T19:05:05+00:00","breadcrumb":{"@id":"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/#primaryimage","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1727118304_Une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/1727118304_Une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab.jpg","width":1280,"height":851,"caption":"Une incidence de r\u00e9ponse \u00e9lev\u00e9e a \u00e9t\u00e9 observ\u00e9e pour l'axatilimab dans le traitement de la maladie du greffon contre l'h\u00f4te r\u00e9fractaire et r\u00e9currente"},{"@type":"BreadcrumbList","@id":"https:\/\/rvh-synergie.org\/actualites\/une-incidence-de-reponse-elevee-a-ete-observee-pour-laxatilimab-dans-le-traitement-de-la-maladie-du-greffon-contre-lhote-refractaire-et-recurrente\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/rvh-synergie.org\/actualites\/"},{"@type":"ListItem","position":2,"name":"Une incidence de r\u00e9ponse \u00e9lev\u00e9e a \u00e9t\u00e9 observ\u00e9e pour l’axatilimab dans le traitement de la maladie du greffon contre l’h\u00f4te r\u00e9fractaire et r\u00e9currente"}]},{"@type":"WebSite","@id":"https:\/\/rvh-synergie.org\/actualites\/#website","url":"https:\/\/rvh-synergie.org\/actualites\/","name":"RVH-Synergie.org","description":"RVH-Synergie, site ind\u00e9pendant d'informations sur la prise en charge des addictions.","publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/rvh-synergie.org\/actualites\/#organization","name":"RVH-Synergie.org","url":"https:\/\/rvh-synergie.org\/actualites\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","width":512,"height":512,"caption":"RVH-Synergie.org"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560","name":"Charles Martinez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","caption":"Charles Martinez"},"description":"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.","sameAs":["https:\/\/rvh-synergie.org\/"]}]}},"_links":{"self":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/comments?post=774"}],"version-history":[{"count":0,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/774\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media\/775"}],"wp:attachment":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media?parent=774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/categories?post=774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/tags?post=774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}